New identity reflects transition in corporate focus, from technology licensing to drug development, for previously untreatable cancers
Newcastle, UK, 10th September, 2018: Glythera Limited (Glythera), the next-generation Antibody Drug Conjugate (ADC) development company, today announced that it has changed its name to Iksuda Therapeutics (Iksuda) and unveiled a new corporate brand. The new identity signifies the Company’s transition from technology licensing to drug development, focusing on cancer therapeutics and the treatment of solid tumours. To coincide with the rebranding, Iksuda Therapeutics has launched a new website: www.iksuda.com
Iksuda’s primary focus will be on the development of superior ADCs for treatment of difficult-to-treat cancers, but the Company will continue to support its partners’ portfolios with its advanced conjugation platform, PermaLink®, and novel toxin payloads.
Iksuda anticipates that it will nominate two ADCs for clinical progression in Q4 2018, with first indications expected to be ovarian and lung cancers. To support its pre-clinical and clinical activities, the Company has significantly expanded its team over the past 12 months, including the appointment of Dr Robert Lutz’s as CSO in January 2018.
Dr Dave Simpson, Chief Executive Officer, Iksuda, said: “The name Iksuda is derived from the Sumerian word for ‘all conquering’ and was chosen to reflect our ambition of overcoming the issue of ADC instability to create a new generation of stable, effective ADCs for treating the most severe cancers and improving patient lives.”
Notes to Editors
For high-resolution images, please contact [email protected]
For further information please contact:
Iksuda Therapeutics
Dave Simpson, Chief Executive Officer
Tel: +44 (0) 191 6031680
Email [email protected]
Website www.iksuda.com
Zyme Communications (Trade and Regional Media)
Lorna Cuddon
Tel: +44 (0) 7811 996 942
FTI Consulting (Financial Media and IR)
Simon Conway / Mo Noonan / Rob Winder
Tel: +44 (0) 020 3727 1000